How do remission and response rates in bright light therapy for seasonal affective disorder differ between treatment courses shorter than two weeks and those lasting at least two weeks?

The short-versus-long comparison comes from non-seasonal depression, not SAD

The question asks about seasonal affective disorder, but the studies that actually split treatment by duration enrolled people with non-seasonal depression. One meta-analysis of 15 randomized trials (883 patients) found bright light therapy reduced depressive symptoms overall, and that trials lasting two weeks or less, or using 60 minutes or more of daily exposure, were associated with higher therapeutic effectiveness [1]. A second meta-analysis of 11 trials (858 patients) found better remission and response rates with light therapy than with control conditions, and its duration subgroups split at four weeks rather than two [2].

The SAD-specific papers do not supply the comparison. A 1995 review of SAD treatments discusses response over time and notes improvement seen in the first one to two weeks of treatment, but it does not analyze short versus long courses [3]. A controlled SAD study compared dawn simulation, bright light, and placebo over a six-week treatment phase without separating shorter from longer courses [4]. An ophthalmologic study of SAD patients evaluated them after roughly two weeks of light treatment and again over years, but its focus was eye safety, not a duration comparison [5].

Why shorter courses could look more effective — and why that can mislead

A plausible reading of the non-seasonal finding is that light therapy acts fairly quickly, so the biggest gains show up early and later weeks add less. The SAD review's note that response is often seen in the first one to two weeks is consistent with that idea [3]. But a subgroup result like "two weeks or less was associated with higher effectiveness" [1] is a comparison across different trials, not a head-to-head test of the same patients on short versus long schedules. Trials of different lengths can differ in who was enrolled, how severe their depression was, and what control condition they used, so the duration label may be carrying other differences with it.

The second meta-analysis illustrates how the choice of cut-point matters. Splitting at four weeks, it found better remission and response rates with light therapy in both the shorter and longer follow-up groups, with the advantage over control appearing somewhat larger in the under-four-week group for remission (27.4% vs 9.2%) and response (55.6% vs 27.4%) than in the over-four-week group (46.6% vs 29.1% and 63.0% vs 44.9%) [2]. That pattern is compatible with early benefit being strong, but it does not establish that stopping before two weeks is better than continuing.

What the numbers actually measure

Remission means symptoms fall below a threshold for being considered largely well; response means a meaningful improvement rather than full recovery. In the non-seasonal meta-analysis, 40.7% of light-therapy patients reached remission versus 23.5% of controls, and 60.4% versus 38.6% responded [2]. Those are endpoint rates pooled across trials of varying length, so they describe how often people improved by the end of treatment, not how quickly.

For SAD, the available papers report remission and response within multi-week protocols rather than as a short-versus-long contrast. The six-week SAD trial reports remission and response over that period [4], and the eye-safety study reports clinical remission after about two weeks of treatment and over longer follow-up [5]. Neither isolates a two-week boundary, so a reader should not treat their rates as evidence that one course length beats the other.

What this means if you are weighing a two-week course

The honest summary is that the direct question — do remission and response rates differ between SAD light-therapy courses under two weeks and courses of at least two weeks — is not answered by these studies. The SAD evidence supports light therapy as a treatment and suggests early improvement is common [3][4][5], while the duration signal favoring shorter courses comes from non-seasonal depression and from between-trial comparisons [1]. Because seasonal and non-seasonal depression differ in their triggers and timing, that signal should be treated as a hypothesis worth testing in SAD, not as a demonstrated difference.

If the practical choice is whether to stop at two weeks or continue, the evidence here offers no basis for saying a shorter course produces higher remission or response in SAD. What it does support is that benefit can appear within the first couple of weeks [3] and that light therapy outperforms control conditions over courses of several weeks [2][4]. Whether extending beyond two weeks adds remission or response in SAD remains an open question that these studies do not resolve.

Sources used in this answer

Related research questions